Highlights

  • Consensus rating of Buy from 7 analysts: 5 Buy or equivalent, 2 Hold, 0 Sell or equivalent.
  • Mean price target of A$3.88 against a share price of A$2.80 on 8 October 2026, an implied upside of 38.6%.
  • Analyst targets range from A$3.20 to A$5.15.
  • Total trophon unit placements rose 9% to 4,230 units and the global cumulative installed base rose 6% to 39,230 devices, with record North American upgrades up 32%.

Nanosonics (ASX:NAN) carries a consensus analyst rating of Buy. Of the 7 analyst recommendations recorded, 5 are Buy or equivalent, 2 are Hold and 0 are Sell or equivalent. The mean price target is A$3.88, with targets ranging from A$3.20 to A$5.15, against a current share price of A$2.80 (8 October 2026). Nanosonics Limited is an infection prevention company known for its trophon ultrasound probe disinfection devices and its developing CORIS endoscope cleaning system.

Company name

Nanosonics

Ticker

(ASX:NAN)

Exchange

ASX (Australian Securities Exchange)

Current share price

A$2.80

Price date

8 October 2026

Number of analysts

7

Rating consensus

Buy

Consensus price target (mean)

A$3.88

Highest target

A$5.15

Lowest target

A$3.20

Implied upside/downside to mean target

Implied upside of 38.6%

Latest developments

Nanosonics (ASX:NAN) announced its FY26 results for the year ended 30 June 2026 on 25 August 2026. Total trophon unit placements rose 9% to 4,230 units and the global cumulative installed base rose 6% to 39,230 devices, with record North American upgrades up 32%. Revenue rose 3% to $203.9 million, or 6% to $211.5 million at constant currency. EBIT was $16.0 million, down 10%, or up 21% to $21.6 million at constant currency. trophon-only EBIT was $50.6 million, up 5%, or up 16% to $56.5 million at constant currency.

Cash and cash equivalents were $155.2 million, including the completion of a $20 million buy-back, with no debt. The company announced a new on-market buy-back of up to $40 million in FY27. The CORIS Controlled Market Release is progressing, with commercial launch planned throughout FY27 across all regions and a step-up in investment.

FY27 guidance at constant currency is revenue of $220 million to $228 million, growth of 8% to 12%, gross Margin of 74% to 76% and operating expenses of $156 million to $163 million, growth of 10% to 15%. The guidance assumes no changes to the global trading environment and US tariffs.

Sector context

The company operates in infection prevention for healthcare, with reported revenue affected by the higher Australian dollar. Its growth depends on trophon installations and upgrades in North America and other regions and on the launch of its next product, CORIS.

Risks and what to watch

Reported EBIT fell 10% because of the higher Australian dollar, and the company notes a step-up in CORIS investment, with operating expenses guided up 10% to 15% in FY27. Guidance assumes no change to the global trading environment and US tariffs. CORIS is still in controlled market release, and its commercial adoption is not yet established.

Next milestones

Items to watch include CORIS commercial launch progress during FY27, delivery against FY27 guidance of $220 million to $228 million in revenue, trophon3 and trophon2 Plus adoption, the $40 million buy-back, and the half-year result.